4-bromo-6-fluoropyridin-2-amine | 1390641-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-bromo-6-fluoropyridin-2-amine
• 英文别名: 2-amino-4-bromo-6-fluoropyridine；4-Bromo-6-fluoropyridin-2-amine
• CAS: 1390641-19-6
• 化学式: C₅H₄BrFN₂
• 分子量: 191.003
• InChiKey: BJNVEINASAHIGF-UHFFFAOYSA-N

物化性质

• 沸点：
  281.9±35.0 °C(Predicted)
• 密度：
  1.813±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-6-fluoropyridin-2-amine 在 盐酸羟胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 生成 7-Bromo-5-fluoro-[1,2,4]triazolo[1,5-A]pyridin-2-amine
  参考文献：
  名称：

  Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease

  摘要：

  Herein, we disclose the discovery of a series of 7-substituted triazolopyridines which culminated in the identification of 14 (CZC24758), a potent, orally bioavailable small-molecule inhibitor of PI3K gamma, an attractive drug target for inflammatory and autoimmune disorders. Compound 14 has excellent selectivity across the kinome, demonstrates good potency in cell based assays and furthermore exhibits in vivo efficacy in a collagen induced arthritis model in mouse after oral dosing. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.090

文献信息

• HETEROCYCLIC AMIDE COMPOUND AND HERBICIDE
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：US20160221998A1

  公开（公告）日：2016-08-04

  Provided are: a heterocyclic amide compound represented by formula (1); and a herbicide containing the heterocyclic amide compound. In the formula, G represents a group represented by formula (G-1) or (G-2); each of W and W 1 independently represents an oxygen atom or the like; each of Z 1 and Z a1 represents a phenyl group or the like; Z 2 represents an aromatic heterocycle; each of R 1 and R 2 independently represents a C 1 -C 6 alkyl group or the like; R 3 represents a hydrogen atom, a C 1 -C 6 alkyl group or the like; and each of R 4 , R a4 , R 5 , R a5 , R 6 , R a6 and R 7 independently represents a hydrogen atom or the like.

  提供的是由式（1）表示的杂环酰胺化合物；以及含有该杂环酰胺化合物的除草剂。在该式中，G代表由式（G-1）或（G-2）表示的基团；W和W1各自独立地代表氧原子或类似物；Z1和Za1各自代表苯基或类似物；Z2代表芳香杂环；R1和R2各自独立地代表C1-C6烷基或类似物；R3代表氢原子、C1-C6烷基或类似物；R4、Ra4、R5、Ra5、R6、Ra6和R7各自独立地代表氢原子或类似物。
• Remote Hydroamination of Disubstituted Alkenes by a Combination of Isomerization and Regioselective N–H Addition
  作者：Senjie Ma、Haoyu Fan、Craig S. Day、Yumeng Xi、John F. Hartwig

  DOI：10.1021/jacs.2c13054

  日期：——

  steric and electronic effects of ligand modules on reactivity and selectivity. The remote hydroamination is compatible with a broad scope of alkenes and aminopyridines and enables the regioconvergent synthesis of amines from an isomeric mixture of alkenes. The products can be derivatized by nucleophilic aromatic substitution on the amino substituent with a variety of nucleophiles.

  烯烃的远程氢功能化包含现有碳-碳双键远端的官能团。虽然远程羰基化是众所周知的，但远程氢功能化最常见的是用烯烃添加相对非极性的 B-H、Si-H 和 C-H 键。我们报道了一种二取代烯烃的远程氢胺化系统，以在亚末端未活化的亚甲基位置选择性地官能化烷基链。高区域选择性和反应速率的关键是取代基在胺上的电子性质以及通过评估配体模块对反应性和选择性的空间和电子效应来开发配体 DIP-Ad-SEGPHOS。远程氢胺化与广泛的烯烃和氨基吡啶兼容，并能够从烯烃的异构体混合物区域收敛合成胺。产物可通过用多种亲核试剂在氨基取代基上进行亲核芳香族取代而衍生化。
• Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease
  作者：Mihiro Sunose、Kathryn Bell、Katie Ellard、Giovanna Bergamini、Gitte Neubauer、Thilo Werner、Nigel Ramsden

  DOI：10.1016/j.bmcl.2012.05.090

  日期：2012.7

  Herein, we disclose the discovery of a series of 7-substituted triazolopyridines which culminated in the identification of 14 (CZC24758), a potent, orally bioavailable small-molecule inhibitor of PI3K gamma, an attractive drug target for inflammatory and autoimmune disorders. Compound 14 has excellent selectivity across the kinome, demonstrates good potency in cell based assays and furthermore exhibits in vivo efficacy in a collagen induced arthritis model in mouse after oral dosing. (C) 2012 Elsevier Ltd. All rights reserved.